Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-Week Study of Ixekizumab in bDMARD-Naive Nonradiographic Axial Spondyloarthritis
jRCT2080223291Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in non-radiographic axial spondyloarthritis (nr-axSpA) (3 arms), sponsored by Eli Lilly and Company. Started Aug 2016; status: recruiting.
02
Drugs
ixekizumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on jRCT2080223291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223291.